Epilepsy & Seizures
Conference Coverage
New data back use of medical cannabis for epilepsy, pain, anxiety
Marijuana products linked to improved symptoms on a variety of fronts, research suggests, and adverse effects seem rare.
FDA/CDC
FDA approves new treatment for Dravet syndrome
Children treated with fenfluramine experienced significantly greater reductions in the frequency of convulsive seizures than did their peers who...
Conference Coverage
Most adult epilepsy-related deaths could be avoided
“The overall mortality is not reducing; people are dying young, and neurologists are really not getting involved.”
Latest News
Today’s top news highlights: Protests and COVID-19 risk, avoidable epilepsy deaths, and more
“There’s going to be a lot of issues coming out of what’s happened in the last week, but one of them is going to be that chains of transmission...
Latest News
Neurologists’ pay gets a boost, most happy with career choice
Neurologists’ average annual income this year rose to $280,000, up from $267,000 last year.
Conference Coverage
Frontal lobe glucose abnormalities may indicate increased SUDEP risk
The idea is to identify those at high risk and then reduce that risk with more aggressive management of seizures or closer monitoring in certain...
Conference Coverage
Patients with epilepsy may underreport seizures, survey finds
Clinicians may underestimate the number of seizures that go unreported, and this disconnect may contribute to complacency about epilepsy treatment...
Latest News
Are patients with epilepsy at increased risk of COVID-19 infection?
The COVID risk may not be elevated, but vigilance and caution are still warranted.
Conference Coverage
Artisanal CBD may provide less seizure control than pharmaceutical CBD
Seizure control and side effect profiles differed between the two preparations.
Conference Coverage
Expert says progress in gut-brain research requires an open mind
“What happens in [the] vagus doesn’t just stay in vagus, but will actually affect our emotions in different ways,” Dr. Cryan said.
Literature Review
As costs for neurologic drugs rise, adherence to therapy drops
In patients with Parkinson’s disease, dementia, and neuropathy, higher out-of-pocket drug prices were associated with lower adherence for common...